PT  - JOURNAL ARTICLE
AU  - Kathryn Westendorf
AU  - Stefanie Žentelis
AU  - Denisa Foster
AU  - Peter Vaillancourt
AU  - Matthew Wiggin
AU  - Erica Lovett
AU  - Robin van der Lee
AU  - Jörg Hendle
AU  - Anna Pustilnik
AU  - J. Michael Sauder
AU  - Lucas Kraft
AU  - Yuri Hwang
AU  - Robert W. Siegel
AU  - Jinbiao Chen
AU  - Beverly A. Heinz
AU  - Richard E. Higgs
AU  - Nicole Kalleward
AU  - Kevin Jepson
AU  - Rodrigo Goya
AU  - Maia A. Smith
AU  - David W. Collins
AU  - Davide Pellacani
AU  - Ping Xiang
AU  - Valentine de Puyraimond
AU  - Marketa Ricicova
AU  - Lindsay Devorkin
AU  - Caitlin Pritchard
AU  - Aoise O’Neill
AU  - Kush Dalal
AU  - Pankaj Panwar
AU  - Harveer Dhupar
AU  - Fabian A. Garces
AU  - Courtney Cohen
AU  - John Dye
AU  - Kathleen E. Huie
AU  - Catherine V. Badger
AU  - Darwyn Kobasa
AU  - Jonathan Audet
AU  - Joshua J. Freitas
AU  - Saleema Hassanali
AU  - Ina Hughes
AU  - Luis Munoz
AU  - Holly C. Palma
AU  - Bharathi Ramamurthy
AU  - Robert W. Cross
AU  - Thomas W. Geisbert
AU  - Vineet Menacherry
AU  - Kumari Lokugamage
AU  - Viktoriya Borisevich
AU  - Iliana Lanz
AU  - Lisa Anderson
AU  - Payal Sipahimalani
AU  - Kizzmekia S. Corbett
AU  - Lingshu Wang
AU  - Eun Sung Yang
AU  - Yi Zhang
AU  - Wei Shi
AU  - Barney S. Graham
AU  - John R. Mascola
AU  - Tara L. Fernandez
AU  - Carl L. Hansen
AU  - Ester Falconer
AU  - Bryan E. Jones
AU  - Bryan C. Barnhart
TI  - LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants
AID  - 10.1101/2021.04.30.442182
DP  - 2021 Jan 01
TA  - bioRxiv
PG  - 2021.04.30.442182
4099  - http://biorxiv.org/content/early/2021/09/09/2021.04.30.442182.short
4100  - http://biorxiv.org/content/early/2021/09/09/2021.04.30.442182.full
AB  - LY-CoV1404 (also known as bebtelovimab) is a highly potent, neutralizing, SARS-CoV-2 spike glycoprotein receptor binding domain (RBD)-specific antibody identified from a convalescent COVID-19 patient sample, obtained approximately 60 days after symptom onset. In pseudovirus studies, LY-CoV1404 retains potent neutralizing activity against numerous variants including B.1.617.2, B.1.1.7, B.1.351, B.1.427/B.1.429, P.1, and B.1.526, binding to these variants in the presence of their underlying RBD mutations (which include K417N, L452R, E484K, and N501Y). LY-CoV1404 also neutralizes multiple isolates of the authentic SARS-CoV-2 virus in two different assays. The RBD positions comprising the LY-CoV1404 epitope are highly conserved, with the exception of N439 and N501; notably the binding and neutralizing activity of LY-CoV1404 is unaffected by the most common mutations at these positions (N439K and N501Y). New variant-resistant treatments such as LY-CoV1404 are desperately needed, given that some of the existing therapeutic antibodies are less effective or ineffective against certain variants and the impact of variants on vaccine efficacy is still poorly understood. The breadth of variant binding, potent neutralizing activity and the relatively conserved epitope suggest that LY-CoV1404 is one in a panel of well-characterized, clinically developable antibodies that could be deployed as potentially long-term solutions to address current and emerging variants.In Brief LY-CoV1404 is a potent SARS-CoV-2-binding antibody that neutralizes all known variants of concern and whose epitope is rarely mutated.HighlightsLY-CoV1404 potently neutralizes SARS-CoV-2 authentic virus and all known variants of concern including the B.1.617.2 (Delta) variantNo loss of potency against currently circulating variantsBinding epitope on RBD of SARS-CoV-2 is rarely mutated in GISAID databaseBreadth of neutralizing activity and potency supports clinical developmentCompeting Interest StatementD.F., P. V., A.P., J.H., J.M.S., R.W.S, J.C., I. H., J. J. F., S. H., H. C. P., B. R., B. A. H., R. W. S., J. C., J. M. S., R. E. H., N. K., and B.E.J. are employees and/or stockholders of Eli Lilly and Company. K.W., S. Z., M.W., E.L., L.K., Y.H., K.J., R.G., M.A.S., D.W.C., D.P., P.X., V.d.P., R.v.d.L., M.R., L.D., C.P., I.L., L.A., P.S., T.L.F., C.L.H, E.F., and B.C.B are employees and stockholders of AbCellera Biologics Inc. AbCellera Biologics Inc. and National Institutes of Health have filed patent applications related to the work described herein (US Patent Application No. 17/192243 and International Patent Application No. PCT/US21/20843, both titled: Anti-Coronavirus Antibodies and Methods of Use).